Assenagon Asset Management S.A. Celldex Therapeutics, Inc. Transaction History
Assenagon Asset Management S.A.
- $47.8 Billion
- Q3 2024
A detailed history of Assenagon Asset Management S.A. transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Assenagon Asset Management S.A. holds 20,946 shares of CLDX stock, worth $540,197. This represents 0.0% of its overall portfolio holdings.
Number of Shares
20,946
Previous 139,162
84.95%
Holding current value
$540,197
Previous $5.15 Million
86.19%
% of portfolio
0.0%
Previous 0.01%
Shares
3 transactions
Others Institutions Holding CLDX
# of Institutions
207Shares Held
67.3MCall Options Held
1.69MPut Options Held
980K-
Wellington Management Group LLP Boston, MA9.24MShares$238 Million0.06% of portfolio
-
Black Rock Inc. New York, NY4.69MShares$121 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.87MShares$99.8 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ3.46MShares$89.2 Million9.64% of portfolio
-
Eventide Asset Management, LLC Boston, MA3.33MShares$85.9 Million1.99% of portfolio
About Celldex Therapeutics, Inc.
- Ticker CLDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,772,400
- Market Cap $1.21B
- Description
- Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...